SCHEMBL6484091

SCHEMBL6484091

ClCc1ccc(-c2ccc3ccccc3c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.55
ESR2 Q92731 3/20 0.55
ALOX5 P09917 1/20 0.48
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
HSD17B1 P14061 1/20 0.47
HSD17B2 P37059 1/20 0.47
CYP2A6 P11509 2/20 0.47
CYP1A2 P05177 2/20 0.47
GSTP1 P09211 1/20 0.45
CYP17A1 P05093 1/20 0.44
CYP19A1 P11511 1/20 0.44
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
LPL P06858 1/20 0.42
LIPG Q9Y5X9 1/20 0.42
KMT2A Q03164 1/20 0.42
CHRNB2 P17787 1/20 0.41
CHRNB4 P30926 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL905392 0.82 CYP2A6 (0.60) ALOX5CYP2A6CYP1A2KMT2AHTR2A
SCHEMBL31355436 0.82 CYP2A6 (0.60) ALOX5CYP2A6CYP1A2KMT2AHTR2A
SCHEMBL29418999 0.82 CYP2A6 (0.60) ALOX5CYP2A6CYP1A2KMT2AHTR2A
SCHEMBL18260181 0.82 ESR1 (0.76) ESR1ESR2ALOX5CA1CA2
SCHEMBL31039575 0.82 ESR1 (0.76) ESR1ESR2ALOX5CA1CA2
SCHEMBL8988444 0.79 ESR1 (0.55) ESR1ESR2ALOX5CA1CA2
SCHEMBL26031791 0.79 ESR1 (0.55) ESR1ESR2ALOX5CA1CA2
SCHEMBL27832338 0.79 TAAR1 (0.61) ESR1ESR2ALOX5CA1CA2
SCHEMBL239121 0.79 ESR1 (0.71) ESR1ESR2ALOX5CA1CA2
SCHEMBL15902840 0.79 ESR1 (0.71) ESR1ESR2ALOX5CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6933322-B2 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2005-08-23 US disclosed
US-20030216442-A1 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus WYETH 2003-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216442-A1 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus INSR, GPR119, SLC5A1 ESR1 1789/4885ESR2 1378/4885ALOX5 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.